These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 34638802)

  • 1. Toll-Like Receptor Response to Hepatitis B Virus Infection and Potential of TLR Agonists as Immunomodulators for Treating Chronic Hepatitis B: An Overview.
    Kayesh MEH; Kohara M; Tsukiyama-Kohara K
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses.
    Ma Z; Zhang E; Yang D; Lu M
    Cell Mol Immunol; 2015 May; 12(3):273-82. PubMed ID: 25418467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toll-like receptor-mediated innate immunity orchestrates adaptive immune responses in HBV infection.
    Du Y; Wu J; Liu J; Zheng X; Yang D; Lu M
    Front Immunol; 2022; 13():965018. PubMed ID: 35967443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of microRNA by hepatitis B virus infection and their possible association with control of innate immunity.
    Jiang X; Kanda T; Wu S; Nakamura M; Miyamura T; Nakamoto S; Banerjee A; Yokosuka O
    World J Gastroenterol; 2014 Jun; 20(23):7197-206. PubMed ID: 24966589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection.
    Zhang E; Lu M
    Med Microbiol Immunol; 2015 Feb; 204(1):11-20. PubMed ID: 25550115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection.
    Meng Z; Chen Y; Lu M
    Front Immunol; 2019; 10():3127. PubMed ID: 32117201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toll-like Receptor Response to Human Immunodeficiency Virus Type 1 or Co-Infection with Hepatitis B or C Virus: An Overview.
    Kayesh MEH; Kohara M; Tsukiyama-Kohara K
    Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepatitis B.
    Ma Z; Cao Q; Xiong Y; Zhang E; Lu M
    Vaccines (Basel); 2018 Jan; 6(1):. PubMed ID: 29337856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activating the innate immune response to counter chronic hepatitis B virus infection.
    Lamb C; Arbuthnot P
    Expert Opin Biol Ther; 2016 Dec; 16(12):1517-1527. PubMed ID: 27603796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased expression of toll like receptor signaling molecules in chronic HBV infected patients.
    Momeni M; Zainodini N; Bidaki R; Hassanshahi G; Daneshvar H; Khaleghinia M; Ebrahim M; Karimi-Googheri M; Askari A; Arababadi MK; Kennedy D
    Hum Immunol; 2014 Jan; 75(1):15-9. PubMed ID: 24120739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells.
    Wu J; Meng Z; Jiang M; Pei R; Trippler M; Broering R; Bucchi A; Sowa JP; Dittmer U; Yang D; Roggendorf M; Gerken G; Lu M; Schlaak JF
    Hepatology; 2009 Apr; 49(4):1132-40. PubMed ID: 19140219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-IL1 receptor-mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated-IFN in HBeAg-positive CHB patients.
    Visvanathan K; Lang T; Ryan K; Wilson R; Skinner NA; Thompson AJ; Ahn SH; Weilert F; Abbott W; Gane E; Colledge D; Li K; Locarnini S; Mansell A; Revill PA
    J Viral Hepat; 2016 Mar; 23(3):170-9. PubMed ID: 26436722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating and Hepatic BDCA1+, BDCA2+, and BDCA3+ Dendritic Cells Are Differentially Subverted in Patients With Chronic HBV Infection.
    Ouaguia L; Leroy V; Dufeu-Duchesne T; Durantel D; Decaens T; Hubert M; Valladeau-Guilemond J; Bendriss-Vermare N; Chaperot L; Aspord C
    Front Immunol; 2019; 10():112. PubMed ID: 30778353
    [No Abstract]   [Full Text] [Related]  

  • 14. Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B.
    Lebossé F; Testoni B; Fresquet J; Facchetti F; Galmozzi E; Fournier M; Hervieu V; Berthillon P; Berby F; Bordes I; Durantel D; Levrero M; Lampertico P; Zoulim F
    J Hepatol; 2017 May; 66(5):897-909. PubMed ID: 28043874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STING agonists induce an innate antiviral immune response against hepatitis B virus.
    Guo F; Han Y; Zhao X; Wang J; Liu F; Xu C; Wei L; Jiang JD; Block TM; Guo JT; Chang J
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1273-81. PubMed ID: 25512416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifaceted Defects in Monocytes in Different Phases of Chronic Hepatitis B Virus Infection: Lack of Restoration after Antiviral Therapy.
    Dey D; Pal S; Chakraborty BC; Baidya A; Bhadra S; Ghosh R; Banerjee S; Ahammed SKM; Chowdhury A; Datta S
    Microbiol Spectr; 2022 Dec; 10(6):e0193922. PubMed ID: 36445121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toll-like receptor dual-acting agonists are potent inducers of PBMC-produced cytokines that inhibit hepatitis B virus production in primary human hepatocytes.
    Janovec V; Hodek J; Clarova K; Hofman T; Dostalik P; Fronek J; Chlupac J; Chaperot L; Durand S; Baumert TF; Pichova I; Lubyova B; Hirsch I; Weber J
    Sci Rep; 2020 Jul; 10(1):12767. PubMed ID: 32728070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants.
    Kayesh MEH; Kohara M; Tsukiyama-Kohara K
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of mRNA expression of toll-like receptor 2 and 3 with hepatitis B viral load in chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
    Kataki K; Borthakur P; Kumari N; Deka M; Kataki AC; Medhi S
    J Med Virol; 2017 Jun; 89(6):1008-1014. PubMed ID: 27769109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between polymorphisms in toll-like receptor genes and the activity of hepatitis B virus among treatment-naïve patients: a case-control study in a Han Chinese population.
    Lin Y; Gao ZX; Shen X; Chen MJ; Li YT; Li SL; Lin HL; Zhao QF; Liu F; Niu JJ
    BMC Infect Dis; 2018 Jan; 18(1):28. PubMed ID: 29320990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.